PAHO study: 470 million in the Americas live with a neurological disorder

A Pan American Health Organization (PAHO) analysis in The Lancet Regional Health – Americas, published in July 2026, finds 470 million people across 38 countries and territories lived with at least one of 19 nervous system disorders in 2023, with disability increasingly outweighing premature mortality.

A large crowd of identical silhouettes in teal fills the frame, with a distinct group highlighted in burnt orange among them.

NEUROLOGY · OCTOBER 31, 2026 · AMERICAS

Neurological disease in the Americas is increasingly a long-term disability problem rather than primarily a mortality problem — a shift with direct consequences for how payers, health systems, and industry budget for dementia, stroke, and migraine care. A study led by the Pan American Health Organization (PAHO), the regional office of the World Health Organization (WHO) for the Americas, published in The Lancet Regional Health – Americas in July 2026, estimates that 470 million people (95% uncertainty interval [UI] 418–523 million) across 38 countries and territories were living with at least one of 19 noncommunicable and injury-related nervous system disorders (NINSDs) in 2023, drawing on estimates from the Global Burden of Disease (GBD) Study 2023. The authors conclude that these conditions impose a substantial and persistent burden, with disability increasingly outweighing premature mortality.

Those conditions caused 1.1 million deaths (95% UI 0.8–1.7 million) and 37.5 million disability-adjusted life years (DALYs — a measure combining years of life lost to premature death and years lived with disability) (95% UI 27.9–51.8 million), representing 12% of the total burden from noncommunicable diseases in the region, according to the study. Migraine, Alzheimer’s disease and other dementias, ischaemic stroke, and intracerebral haemorrhage were the leading contributors to DALYs.

470 million

An estimated 470 million people across 38 countries and territories in the Americas were living with at least one nervous system disorder in 2023, per the PAHO-led GBD Study 2023 analysis.

A burden shifting from mortality toward chronic disability

The epidemiological trend embedded in the data is the more consequential signal for health-system planners. From 1990 to 2023, age-standardised DALY rates declined for ischaemic stroke, haemorrhagic stroke, and neural tube defects — conditions whose decline the study does not attribute to a specific cause. At the same time, rates increased for neurodegenerative disorders, including multiple sclerosis and motor neuron diseases, per the study. The authors summarise the pattern as disability increasingly outweighing premature mortality.

“More people now survive neurological disorders, but they also live longer with their consequences,” said Ramón Martínez, PAHO health metrics specialist and the study’s lead author, in PAHO’s 22 July 2026 release (translated from Spanish). The authors call for expanding long-term care, rehabilitation, and disability support — a demand that, in HealthSignals’ assessment, sits uneasily with acute-care-oriented systems.

Modifiable risk factors and the cardiometabolic link

The study’s risk-factor findings draw a direct line between neurological burden and cardiometabolic control — a connection with implications for how prevention programmes are designed and funded. High systolic blood pressure was identified as the leading modifiable risk factor for stroke subtypes, and high fasting plasma glucose as the leading risk factor for dementias, per the study. The authors also found that lead exposure accounted for nearly 60% of DALYs from idiopathic intellectual disability in the region.

The dementia-glucose link is analytically significant because it positions diabetes management as a potential upstream lever for neurological burden reduction. The study does not establish a causal pathway between glycaemic control interventions and dementia incidence; the association is observational, and the authors frame it as a rationale for integrating neurological health into noncommunicable disease strategies rather than as evidence of a demonstrated preventive effect.

The lead-exposure finding carries a different policy character: it points to an environmental and regulatory intervention — stricter controls on industrial pollution, remediation of contaminated sites, and elimination of lead in paints and plumbing — rather than a pharmaceutical one. The study covers 38 countries with heterogeneous regulatory environments, and the feasibility of coordinated environmental enforcement varies substantially across the region.

What to Watch

  1. Whether national health-technology assessment bodies — including Brazil’s CONITEC, the Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (SUS), which advises on public-health-system coverage, and Colombia’s IETS (Instituto de Evaluación Tecnológica en Salud) — incorporate the GBD 2023 regional burden estimates into forthcoming neurology coverage reviews.
  2. How rehabilitation and long-term care capacity investments are reflected in national health budgets across the region, given the study’s finding that disability is increasingly outweighing premature mortality in the region’s neurological burden.
  3. Progress on environmental lead-exposure regulation across Latin American jurisdictions, given the study’s estimate that lead accounts for nearly 60% of DALYs from idiopathic intellectual disability in the Americas.

The study’s authors declare no funding. A PAHO-led, GBD-anchored estimate covering all 38 countries and territories in a single methodological framework provides a regional baseline — though the GBD methodology itself depends on the quality of national disease registries, which varies considerably across the region.

Nervous System Disorder Burden in the Americas · 2023

Point Estimate 95% Uncertainty Interval
People living with at least one NINSD 470 million 418–523 million
Deaths attributed to NINSDs 1.1 million 0.8–1.7 million
DALYs attributed to NINSDs 37.5 million 27.9–51.8 million
NINSDs as share of total noncommunicable disease burden 12%

Source: PAHO / The Lancet Regional Health – Americas, GBD Study 2023 (published 2026-07-20). Study covered 38 countries and territories, assessed 19 noncommunicable and injury-related nervous system disorders over 1990–2023.

Why this is relevant

Patients

The study finds disability increasingly outweighing premature mortality in the neurological burden of the Americas, meaning many of the 470 million people living with at least one nervous system disorder face years of functional limitation — a shift that calls for expanded rehabilitation and continuous care services across the region.

Industry

The identification of high fasting plasma glucose as the leading modifiable risk factor for dementias, and rising age-standardised DALY rates for multiple sclerosis and motor neuron diseases, may suggest growing addressable demand for dementia diagnostics, cardiometabolic prevention programmes, and neurodegenerative disease management across Latin American health systems.

Payers

The pattern of disability increasingly outweighing premature mortality, documented across 38 countries using GBD 2023 estimates, appears consistent with a structural shift in neurological cost drivers — from episodic hospital spending toward sustained rehabilitation, multidisciplinary management, and long-term care capacity that many regional payer frameworks may not yet reflect.

Regulators

The study, led by PAHO and published in The Lancet Regional Health – Americas with no declared funding, provides a PAHO-anchored burden baseline that national health-technology assessment bodies such as Brazil’s CONITEC may draw on in forthcoming neurology coverage reviews, while the lead-exposure finding — nearly 60% of DALYs from idiopathic intellectual disability — falls to environmental regulators.

THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

Sources: The Lancet Regional Health – Americas: The burden of noncommunicable and injury-related nervous system disorders in the Americas, 1990–2023 · PAHO: Dos de cada cinco personas en las Américas viven con una afección neurológica, según un nuevo estudio (22 July 2026)

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related